Clinical Characteristics and Disease Course in Patients Treated With Efalizumab Following Suspension of Marketing Authorization by the European Medicines Agency: A Multicenter Observational Study

✍ Scribed by L. Morell; J.M. Carrascosa; C. Ferrándiz; M. García-Bustinduy; E. Fonseca; G. Carretero; E. Daudén; S.E. Marrón; J.L. López-Estebaranz; M. Ferrán; M. Sánchez-Regaña; C. Muñoz-Santos; I. Belinchón; Luis Puig

• Book ID: 119628377
• Publisher: Elsevier Science
• Year: 2011
• Tongue: Spanish
• Weight: 239 KB
• Volume: 102
• Category: Article
• ISSN: 0001-7310
• DOI: 10.1016/s1578-2190(11)70818-6